| Field | Specification |
|---|---|
| Alternative names | 125B11 hydrobromide |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C18H19BrN2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Fatostatin hydrobromide, also known as 125B11 hydrobromide, specifically inhibits SREBP activation and impairs activation of both SREBP-1 and SREBP-2. It binds SCAP (SREBP cleavage-activating protein) and blocks the ER-Golgi translocation of SREBPs, thereby reducing transcription of lipogenic genes in cells. The compound has antitumor properties and lowers hyperglycemia in ob/ob mice[1][2]. It is supplied as a light yellow to yellow solid (C18H19BrN2S, MW 375.33) at 99.52% purity.
Physical & Chemical Properties
| CAS Number | 298197-04-3 |
|---|---|
| Molecular Formula | C18H19BrN2S |
| Molecular Weight | 375.33 g/mol |
| Purity | 99.52% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | CCCC1=NC=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=C1.[H]Br |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: 25 mg/mL (66.61 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 25 mg/mL (66.61 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 1 mg/mL (2.66 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 1 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) suppresses proliferation of androgen-independent prostate cancer cells (IC50=0.1 μM), independent of the known IGF1-signaling pathway. Fatostatin hydrobromide also blocks insulin-induced adipogenesis in 3T3-L1 cells[1].
Cell Proliferation Assay[1]
| Cell Line | DU-145 cells |
|---|---|
| Concentration | 0.1, 1 μM |
| Incubation Time | 3 days |
| Result | Impaired the IGF1-induced growth at an IC50 of 0.1 μM. |
In Vivo
Daily i.p. dosing of Fatostatin hydrobromide (125B11 hydrobromide) at 30 mg/kg (150 mL) for 28 days lowers adiposity, improves fatty liver by decreasing triglyceride (TG) storage, and reduces hyperglycemia in ob/ob mice[2].
| Animal Model | Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)[2] |
|---|---|
| Dosage | 30 mg/kg; 150 mL |
| Administration | i.p. injection; daily for 28 days |
| Result | Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
A metabolic alarmin from keratinocytes potentiates systemic humoral immunity. Nature 2026 Apr;652(8108):209-219. PMID: 41781621
Midkine as a driver of age-related changes and increase in mammary tumorigenesis. Cancer Cell 2024 Nov 11;42(11):1936-1954.e9. PMID: 39366375
TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis. Cell Metab 2021 Aug 3;33(8):1655-1670.e8. PMID: 34015269
YDJC restrains Th1 cell differentiation by blocking SREBP2-mediated cholesterol biosynthesis to alleviate mucosal inflammation in inflammatory bowel disease. Cell Mol Immunol 2025 Oct 29. PMID: 41162693
Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. Autophagy 2021 Jul;17(7):1592-1613. PMID: 32432943
The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. Nat Commun 2026 Jan 20;17(1):614. PMID: 41559041
Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. Nat Commun 2025 Feb 25;16(1):1774. PMID: 40000627
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism. Nat Commun 2025 Feb 1;16(1):1241. PMID: 39890808
ICOS regulates IL-10 production in group 2 innate lymphoid cells via cholesterol and cortisol biosynthesis. J Clin Invest 2025 Jul 8:e193134. PMID: 40627441
The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming. J Exp Clin Cancer Res 2019 May 29;38(1):228.
